ArticleDiscover oncology2026
LncRNA MCF2L-AS1 promotes malignant progression of colorectal cancer by post-transcriptional activation of MCF2L.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo elucidate the functional role of MCF2L antisense RNA1 (MCF2L-AS1) in colorectal cancer (CRC) progression and its potential molecular mechanism.
methodsThe expression of MCF2L-AS1/MCF2L in CRC cell lines was detected by qRT-PCR. The biological function of MCF2L-AS1 was investigated in vitro and in vivo (colony formation, CCK8, Apoptosis assays, wound healing and transwell assays, and mouse xenograft models). Mechanistic investigations involved bioinformatics analysis followed by experimental validation using Fluorescence in situ hybridization, RNA pull-down, and RNA immunoprecipitation.
resultsMCF2L-AS1 was notably upregulated in CRC tissues and cells. Functionally, MCF2L-AS1 suppression markedly attenuated the viability and colony capacity of CRC cells, and the number of migratory and invasive cells was markedly reduced both in vivo and in vitro. Mechanism studies have shown that MCF2L-AS1 binds to the heterogeneous nuclear ribonucleoprotein AUF1, facilitating MCF2L protein synthesis through a post-transcriptional regulatory mechanism independent of mRNA stability.
conclusionsMCF2L-AS1 promotes CRC progression through AUF1-dependent translational regulation of MCF2L expression. MCF2L-AS1 may represents a potential therapeutic target for clinical intervention in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.